PROCTER & GAMBLE HEALTH | ZYDUS LIFESCIENCES | PROCTER & GAMBLE HEALTH/ ZYDUS LIFESCIENCES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.6 | 32.3 | 107.2% | View Chart |
P/BV | x | 10.6 | 5.4 | 193.8% | View Chart |
Dividend Yield | % | 2.0 | 0.6 | 317.7% |
PROCTER & GAMBLE HEALTH ZYDUS LIFESCIENCES |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Jun-23 |
ZYDUS LIFESCIENCES Mar-23 |
PROCTER & GAMBLE HEALTH/ ZYDUS LIFESCIENCES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5,366 | 495 | 1,084.1% | |
Low | Rs | 3,883 | 319 | 1,215.7% | |
Sales per share (Unadj.) | Rs | 740.7 | 170.3 | 435.0% | |
Earnings per share (Unadj.) | Rs | 138.2 | 19.8 | 698.9% | |
Cash flow per share (Unadj.) | Rs | 155.2 | 26.9 | 576.4% | |
Dividends per share (Unadj.) | Rs | 95.00 | 6.00 | 1,583.3% | |
Avg Dividend yield | % | 2.1 | 1.5 | 139.4% | |
Book value per share (Unadj.) | Rs | 447.6 | 173.0 | 258.7% | |
Shares outstanding (eoy) | m | 16.60 | 1,012.20 | 1.6% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.2 | 2.4 | 261.1% | |
Avg P/E ratio | x | 33.5 | 20.6 | 162.5% | |
P/CF ratio (eoy) | x | 29.8 | 15.1 | 197.0% | |
Price / Book Value ratio | x | 10.3 | 2.4 | 439.0% | |
Dividend payout | % | 68.7 | 30.3 | 226.5% | |
Avg Mkt Cap | Rs m | 76,761 | 412,144 | 18.6% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 2,062 | 24,564 | 8.4% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 12,296 | 172,374 | 7.1% | |
Other income | Rs m | 184 | 4,746 | 3.9% | |
Total revenues | Rs m | 12,480 | 177,120 | 7.0% | |
Gross profit | Rs m | 3,247 | 29,677 | 10.9% | |
Depreciation | Rs m | 281 | 7,227 | 3.9% | |
Interest | Rs m | 8 | 1,299 | 0.6% | |
Profit before tax | Rs m | 3,142 | 25,897 | 12.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 847 | 5,878 | 14.4% | |
Profit after tax | Rs m | 2,295 | 20,019 | 11.5% | |
Gross profit margin | % | 26.4 | 17.2 | 153.4% | |
Effective tax rate | % | 27.0 | 22.7 | 118.8% | |
Net profit margin | % | 18.7 | 11.6 | 160.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,713 | 100,082 | 11.7% | |
Current liabilities | Rs m | 6,791 | 55,267 | 12.3% | |
Net working cap to sales | % | 40.0 | 26.0 | 154.0% | |
Current ratio | x | 1.7 | 1.8 | 95.2% | |
Inventory Days | Days | 263 | 50 | 522.4% | |
Debtors Days | Days | 343 | 94 | 367.3% | |
Net fixed assets | Rs m | 10,617 | 144,776 | 7.3% | |
Share capital | Rs m | 166 | 1,012 | 16.4% | |
"Free" reserves | Rs m | 7,265 | 174,146 | 4.2% | |
Net worth | Rs m | 7,431 | 175,158 | 4.2% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 22,330 | 244,940 | 9.1% | |
Interest coverage | x | 409.1 | 20.9 | 1,953.8% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.6 | 0.7 | 78.2% | |
Return on assets | % | 10.3 | 8.7 | 118.5% | |
Return on equity | % | 30.9 | 11.4 | 270.2% | |
Return on capital | % | 42.4 | 15.5 | 273.0% | |
Exports to sales | % | 0 | 39.2 | 0.0% | |
Imports to sales | % | 13.1 | 11.9 | 109.5% | |
Exports (fob) | Rs m | NA | 67,577 | 0.0% | |
Imports (cif) | Rs m | 1,605 | 20,544 | 7.8% | |
Fx inflow | Rs m | 1,465 | 67,577 | 2.2% | |
Fx outflow | Rs m | 1,605 | 20,544 | 7.8% | |
Net fx | Rs m | -140 | 47,033 | -0.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,360 | 26,888 | 8.8% | |
From Investments | Rs m | -215 | 11,712 | -1.8% | |
From Financial Activity | Rs m | -985 | -44,004 | 2.2% | |
Net Cashflow | Rs m | 1,160 | -5,338 | -21.7% |
Indian Promoters | % | 0.0 | 75.0 | - | |
Foreign collaborators | % | 51.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 20.0 | 18.4 | 108.8% | |
FIIs | % | 6.2 | 5.7 | 109.1% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 48.2 | 25.0 | 192.6% | |
Shareholders | 56,778 | 294,324 | 19.3% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare PROCTER & GAMBLE HEALTH With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB SUPRIYA LIFESCIENCE
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Procter & Gamble Health | Cadila Healthcare | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.43% | -0.59% | 0.45% |
1-Month | -1.15% | -6.90% | 2.55% |
1-Year | 0.73% | 83.54% | 56.14% |
3-Year CAGR | -8.76% | 18.56% | 15.22% |
5-Year CAGR | 4.97% | 23.65% | 19.63% |
* Compound Annual Growth Rate
Here are more details on the Procter & Gamble Health share price and the Cadila Healthcare share price.
Moving on to shareholding structures...
The promoters of Procter & Gamble Health hold a 51.8% stake in the company. In case of Cadila Healthcare the stake stands at 75.0%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Procter & Gamble Health and the shareholding pattern of Cadila Healthcare.
Finally, a word on dividends...
In the most recent financial year, Procter & Gamble Health paid a dividend of Rs 95.0 per share. This amounted to a Dividend Payout ratio of 68.7%.
Cadila Healthcare paid Rs 6.0, and its dividend payout ratio stood at 30.3%.
You may visit here to review the dividend history of Procter & Gamble Health, and the dividend history of Cadila Healthcare.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.